ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-dsDNA"

  • Abstract Number: 578 • 2015 ACR/ARHP Annual Meeting

    Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors

    Ran Matsudaira1,2, Naoto Tamura3, Yoshichika Sugisaki2, Tomoko Ito4, Kentaro Minowa2, Michihiro Ogasawara2, Ken Yamaji2, Yoshinori Kanai1, Kenjiro Yamanaka1 and Yoshinari Takasaki2, 1Division of Internal Medicine and Rheumatology, Sasaki institute Kyoundo Hospital, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, 3Department of Internal Medicien and Rheumatology, Juntendo University, School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: The production of autoantibodies, such as anti-nuclear antibodies (ANA) and anti-ds DNA antibodies (anti-DNA), is commonly observed in patients who have been treated with…
  • Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting

    Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States

    Stuart L. Silverman1, Derren Barken2, John Conklin3, Claudia Ibarra4 and Thierry Dervieux5, 1OMC Clinical Research Center, Beverly Hills, CA, 2Exagen Diagnostics, Vista, CA, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Clinical Laboratory, Exagen Diagnostics, Vista, CA, 5Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…
  • Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

    Christian Goess1, Candace Graff2, Ting Ting Zhang2, Gregory Preston2, Richard McCarthy1, Matthew Perham1, Jacqueline Loud1, Christopher M. Harris1, Sara Murdock1, Erik Sampson3, Michael Hoemann4, Michael Friedman4, Robert Talanian3, Jeremy Edmunds4 and Andrew Long1, 1Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
  • Abstract Number: 1121 • 2015 ACR/ARHP Annual Meeting

    Breach of B Cell Anergy in New Zealand Black Congenic Mice

    Kieran Manion1,2, Yuriy Baglaenko1,2, Nan-Hua Chang3 and Joan Wither3, 1Immunology, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada

    Background/Purpose: Anti-DNA B cells are a primary cause of pathology in individuals with systemic lupus erythematosus (SLE), producing autoantibodies that deposit in diverse tissues and…
  • Abstract Number: 1614 • 2014 ACR/ARHP Annual Meeting

    Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity

    Rachael Hawtin1, Wouter Korver2, Erik Evensen2, Diane Longo2, Drew Hotson2, Nikil Wale2, Andy Conroy2, Alessandra Cesano2, Barbara Mittleman2, Tsung Lin3, Vikram R. Rao4, Elena Peeva5, Stephen Benoit5, Martin Hodge3, James D. Clark3, Aaron R. Winkler6 and Jean-Baptiste Telliez3, 1Nodality Inc., South San Francisco, CA, 2Nodality, Inc., South San Francisco, CA, 3Immunoscience, Pfizer Biotherapeutics Research and Development, Cambridge, MA, 4Inflammation & Remodeling, Pfizer, Cambridge, MA, 5Precision Medicine, Pfizer Biotherapeutics Research and Development, Cambridge, MA, 6Inflammation and Remodeling, Pfizer Biotherapeutics Research and Development, Cambridge, MA

    Background/Purpose: Interferons (IFN) reportedly are central to SLE pathogenesis and increased expression of IFN regulated genes (the ‘IFN signature') is associated with active disease. Clinical…
  • Abstract Number: 1606 • 2014 ACR/ARHP Annual Meeting

    Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis   Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity

    Quan-Zhen Li Li1, Edward Wakeland2, Prithvi Raj3, Honglin Zhu2, Xiaoxia Zuo4, Mei Yan5 and Indu Raman6, 1Immunology and internal medicine, University of Texas Southwestern Medical Center, Dallas, TX, 2Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 3Immunology, University of Texas Southwestern Medical Center, dallas, TX, 4Rheumatology, Xiangya Hospital of Hunan Medical Univ, Changsha, China, 5Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, 6Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Autoantibodies targeting to nuclear antigens are serological hallmarks of SLE, however, the processing of autoantibody production during the transition from normal to autoimmunity and…
  • Abstract Number: 640 • 2014 ACR/ARHP Annual Meeting

    A Peptide Mimic Inhibits the Cross Reaction of Anti-DNA Antibodies with Glomerular Antigens

    Yumin Xia1, Ertan Eryilmaz2, Rahul Pawar1, David Cowburn2 and Chaim Putterman3, 1Albert Einstein College of Medicine, Bronx, NY, 2Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, 3The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high titers of multiple autoantibodies. Of those, anti-DNA antibodies play a key role in…
  • Abstract Number: 2525 • 2013 ACR/ARHP Annual Meeting

    An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus

    Chaim Putterman1, Richard Furie2, R. Ramsey-Goldman3, Anca Askanase4, Jill P. Buyon5, Kenneth C. Kalunian6, W. Winn Chatham7, Elena M. Massarotti8, Emily C. Somers9, Irene Blanco10, Puja Chitkara11, Nicole Jordan12, Kyriakos A. Kirou13, Arthur Weinstein14, Susan Manzi15, Joseph M. Ahearn16, Claudia Ibarra17, Derren Barken18 and Thierry Dervieux19, 1Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2North Shore-LIJ Health System, Lake Success, NY, 3Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4NYU School of Medicine, New York, NY, 5Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 6UCSD School of Medicine, La Jolla, CA, 7University of Alabama at Birmingham, Birmingham, AL, 8Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 9IntMed, Environmental Health, and OB/GYN, University of Michigan, Ann Arbor, MI, 10Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 11Rheumatology, SDAMC, San Diego, CA, 12Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 13Hospital for Special Surgery, New York, NY, 14Washington Hospital Center, Washington, DC, 15Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 16Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 17Clinical Laboratory, Exagen Diagnostics, Vista, CA, 18Exagen Diagnostics, Vista, CA, 19Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose: We previously established the value of cell-bound complement activation products (CBCAPS) in the diagnosis of systemic lupus erythematosus (SLE) (CAPITAL study). The purpose of…
  • Abstract Number: 2508 • 2013 ACR/ARHP Annual Meeting

    Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort

    Murray B. Urowitz1, Dafna D. Gladman1, Nicole Anderson1 and Systemic Lupus Erythematosus International Collaborating Clinics SLICC2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Anti-DNA antibodies and serum complement levels are considered important biomarkers for disease activity in SLE.  Despite this many SLE patients present serologically active (positive…
  • Abstract Number: 1648 • 2013 ACR/ARHP Annual Meeting

    PD-1+CD45RBlo122lo Autoantibody-Inducing CD4 T Cells (aiCD4 T cells) As a Key In The Pathogenesis Of Systemic Lupus Erythematosus (SLE)

    Yumi Miyazaki1, Ken Tsumiyama2 and Shunichi Shiozawa1, 1Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 2Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose:  We found that systemic lupus erythematosus (SLE) was induced experimentally by repeatedly immunizing the mice normally not prone to autoimmune diseases by any exogenous…
  • Abstract Number: 1623 • 2013 ACR/ARHP Annual Meeting

    Differential Methylation Of Interferon-Related Genes Is Associated With Anti-dsDNA Autoantibody Production In Systemic Lupus Erythematosus

    Sharon A. Chung1, Joanne Nititham2, Kimberly E. Taylor1, Emon Elboudwarej3, Hong L. Quach3, Lisa F. Barcellos3 and Lindsey A. Criswell2, 1University of California, San Francisco, San Francisco, CA, 2Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 3Epidemiology, University of California, Berkeley, Berkeley, CA

    Background/Purpose: DNA methylation studies in systemic lupus erythematosus (SLE) have shown that SLE patients have less methylation in genes regulating the immune response compared to…
  • Abstract Number: 2313 • 2012 ACR/ARHP Annual Meeting

    The Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) Belongs to CCR4+CD45RBlo122lo CD4 Subpopulation: A Novel ‘Self-Organized Criticality Theory’ Explains the Cause of Systemic Lupus Erythematosus (SLE)

    Yumi Miyazaki1, Ken Tsumiyama2 and Shunichi Shiozawa2, 1Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, 2Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose:  We found that systemic lupus erythematosus (SLE) was induced experimentally by repeatedly immunizing the mice normally not prone to autoimmune diseases by any exogenous…
  • Abstract Number: 1741 • 2012 ACR/ARHP Annual Meeting

    Suppression of Glomerulonephritis in NZB/W F1 Mice by a Selective Inhibitor of Bruton’s Tyrosine Kinase (RN486)

    Paola Mina-Osorio1, Jacob LaStant1, Natalie Keirstead1, Toni Whittard1, Stella Stefanova1, Alka Patel1, Jennifer Postelnek1, John Woods2, Soo Min2, Yong Kim1, Julie Demartino2, Satwant Narula3 and Daigen Xu1, 1Inflammation, Hoffmann-La Roche, Nutley, NJ, 2Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, 3Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ

    Background/Purpose: Bruton tyrosine kinase (Btk) is a Tec family kinase that participates in B cell receptor (BCR), Toll-like Receptor (TLR) and chemokine receptor signaling. It…
  • Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting

    Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy

    Jill P. Buyon1, Aanam Aslam2, Marta M. Guerra2, Michael D. Lockshin3, Carl A. Laskin4, Ware Branch5, Lisa R. Sammaritano6, Michelle Petri7, Joan T. Merrill8, Allen D. Sawitzke9 and Jane E. Salmon6, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 4University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 5Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT

    Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
  • Abstract Number: 1388 • 2012 ACR/ARHP Annual Meeting

    Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms

    Michele Compagno1, Søren Jacobsen2, Ole Petter Rekvig3, Lennart Truedsson4, Niels H. H. Heegaard5, Johannes C. Nossent6, Andreas Jönsen1, Rasmus Sleimann Jacobsen7, Gro Østli Eilertsen6, Gunnar K. Sturfelt8 and Anders Bengtsson1, 1Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, 2Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 3Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, 4Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, 5Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 6Dept of Rheumatology, University of Tromsø, Tromso, Norway, 7Department of Infectious Diseases and Rheumatology, Section 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 8Department of Rheumatology, University Hospital Lund, Lund, Sweden

    Background/Purpose: Anti-dsDNA antibodies are widely used in diagnostic settings when SLE is suspected. Crithidia Luciliae Immunofluorescence Test (CLIFT) and Enzyme Linked ImmunoSorbent Assay (ELISA) are…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology